View Item 

Show simple item record

ACCELERATED DOSING FREQUENCY OF A PULMONARY FORMULATION OF TISSUE PLASMINOGEN ACTIVATOR IS WELL-TOLERATED IN MICE
dc.contributor.authorStringer, Kathleen A.en_US
dc.contributor.authorTobias, Meghanen_US
dc.contributor.authorDunn, John S.en_US
dc.contributor.authorCampos, Jackieen_US
dc.contributor.authorVan Rheen, Zacharyen_US
dc.contributor.authorMosharraf, Mitraen_US
dc.contributor.authorNayar, Rajiven_US
dc.date.accessioned2010-06-01T19:26:15Z
dc.date.available2010-06-01T19:26:15Z
dc.date.issued2008-12en_US
dc.identifier.citationStringer, Kathleen A; Tobias, Meghan; Dunn, John S; Campos, Jackie; Van Rheen, Zachary; Mosharraf, Mitra; Nayar, Rajiv (2008). "ACCELERATED DOSING FREQUENCY OF A PULMONARY FORMULATION OF TISSUE PLASMINOGEN ACTIVATOR IS WELL-TOLERATED IN MICE." Clinical and Experimental Pharmacology and Physiology 35(12): 1454-1460. <http://hdl.handle.net/2027.42/72578>en_US
dc.identifier.issn0305-1870en_US
dc.identifier.issn1440-1681en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72578
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18671720&dopt=citationen_US
dc.format.extent270288 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Asiaen_US
dc.rights© 2008 Blackwell Publishing Asia Pty Ltden_US
dc.subject.otherB6C3F1 Miceen_US
dc.subject.otherHaemorrhageen_US
dc.subject.otherNebulizationen_US
dc.subject.otherPulmonary Drug Deliveryen_US
dc.subject.otherTissue Plasminogen Activatoren_US
dc.titleACCELERATED DOSING FREQUENCY OF A PULMONARY FORMULATION OF TISSUE PLASMINOGEN ACTIVATOR IS WELL-TOLERATED IN MICEen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelPhysiologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Clinical, Social and Administrative Sciences, University of Michigan, College of Pharmacy, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationother* Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, Colorado,en_US
dc.contributor.affiliationotherHTD Biosystems, Hercules, California anden_US
dc.identifier.pmid18671720en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72578/1/j.1440-1681.2008.05011.x.pdf
dc.identifier.doi10.1111/j.1440-1681.2008.05011.xen_US
dc.identifier.sourceClinical and Experimental Pharmacology and Physiologyen_US
dc.identifier.citedreferenceCooper P, Potter S, Mueck B, Yousefi S, Jarai G. Identification of genes induced by inflammatory cytokines in airway epithelium. Am. J. Physiol. Lung Cell Mol. Physiol. 2001; 280: L841 – 52.en_US
dc.identifier.citedreferenceStringer KA, Dunn JS, Gustafson DL. Administration of exogenous tissue plasminogen activator reduces oedema in mice lacking the tissue plasminogen activator gene. Clin. Exp. Pharmacol. Physiol. 2004; 31: 327 – 30.en_US
dc.identifier.citedreferenceHu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J. Biol. Chem. 2006; 281: 2120 – 7.en_US
dc.identifier.citedreferenceRenckens R, Roelofs JJ, Florquin S et al. Endogenous tissue-type plasminogen activator is protective during Escherichia coli -induced abdominal sepsis in mice. J. Immunol. 2006; 177: 1189 – 96.en_US
dc.identifier.citedreferenceStringer KA, Bose SK, McCord JM. Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Free Radic. Biol. Med. 1997; 22: 985 – 8.en_US
dc.identifier.citedreferenceStringer KA. Tissue plasminogen activator inhibits reactive oxygen species production by macrophages. Pharmacotherapy 2000; 20: 375 – 9.en_US
dc.identifier.citedreferenceStringer KA, Lindenfeld J, Repine AJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro. Inflammation 1997; 21: 27 – 34.en_US
dc.identifier.citedreferenceStringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic. Biol. Med. 1998; 25: 184 – 8.en_US
dc.identifier.citedreferenceMacLaren R, Stringer KA. Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome. Pharmacotherapy 2007; 27: 860 – 73.en_US
dc.identifier.citedreferenceMatthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: Four decades of inquiry into pathogenesis and rational management. Am. J. Respir. Cell Mol Biol. 2005; 33: 319 – 27.en_US
dc.identifier.citedreferenceDunn JS, Nayar R, Campos J et al. Feasibility of tissue plasminogen activator formulated for pulmonary delivery. Pharm. Res. 2005; 22: 1700 – 7.en_US
dc.identifier.citedreferenceGardell SJ. The search for the ideal thrombolytic agent: Maximize the benefit and minimize the risk. Toxicol. Pathol. 1993; 21: 190 – 8.en_US
dc.identifier.citedreferenceSimoons ML. Risk–benefit of thrombolysis. Cardiol. Clin. 1995; 13: 339 – 45.en_US
dc.identifier.citedreferenceKorninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 1981; 46: 561 – 5.en_US
dc.identifier.citedreferenceKueltzo L. Ultraviolet absorption spectroscopy. In: Jiskoot W, Crommelin DJ (eds). Methods for Structural Analysis of Protein Pharmaceuticals. American Association of Pharmaceutical Scientists, Arlington. 2005; 1 – 25.en_US
dc.identifier.citedreferenceHermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm. Sci. 2006; 95: 1084 – 96.en_US
dc.identifier.citedreferenceSherman PM, Lawrence DA, Verhamme IM, Paielli D, Shore JD, Ginsburg D. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. J. Biol. Chem. 1995; 270: 9301 – 6.en_US
dc.identifier.citedreferenceMacDonald ME, van Zonneveld AJ, Pannekoek H. Functional analysis of the human tissue-type plasminogen activator protein: The light chain. Gene 1986; 42: 59 – 67.en_US
dc.identifier.citedreferencevan Zonneveld AJ, Veerman H, MacDonald ME, van Mourik JA, Pannekoek H. Structure and function of human tissue-type plasminogen activator (t-PA). J. Cell. Biochem. 1986; 32: 169 – 78.en_US
dc.identifier.citedreferenceKuschel M, Neumann T, Barthmaier P, Kratzmeier M. Use of lab-on-a-chip technology for protein sizing and quantitation. J. Biol. Tech. 2002; 13: 172 – 8.en_US
dc.identifier.citedreferenceLauer JE, Heger JJ, Mirro MJ. Hemorrhagic complications of thrombolytic therapy. Chest 1995; 108: 1520 – 3.en_US
dc.identifier.citedreferenceLansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: A review of the risk factors. Cerebrovasc. Dis. 2007; 24: 1 – 10.en_US
dc.identifier.citedreferenceKristof AS, Goldberg P, Laubach V, Hussain SNA. Role of inducible nitric oxide synthase in endotoxin-induced acute lung injury. Am. J. Respir. Cell Mol. Biol. 1998; 158: 1883 – 9.en_US
dc.identifier.citedreferenceParker JC, Townsley MI. Evaluation of lung injury in rats and mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2004; 286: L231 – 46.en_US
dc.identifier.citedreferenceStringer KA, Freed BM, Dunn JS, Sayers S, Gustafson DL, Flores SC. Particulate phase cigarette smoke increases MnSOD, NQO1, and CINC-1 in rat lungs. Free Radic. Biol. Med. 2004; 37: 1527 – 33.en_US
dc.identifier.citedreferenceSmith PK, Krohn RI, Hermanson GT et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985; 150: 76 – 85.en_US
dc.identifier.citedreferenceDecker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 1988; 115: 61 – 9.en_US
dc.identifier.citedreferenceCard JW, Carey MA, Bradbury JA et al. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J. Immunol. 2006; 177: 621 – 30.en_US
dc.identifier.citedreferenceReinhard C, Eder G, Fuchs H, Ziesenis A, Heyder J, Schulz H. Inbred strain variation in lung function. Mamm. Genome 2002; 13: 429 – 37.en_US
dc.identifier.citedreferenceLi YJ, Kawada T, Matsumoto A et al. Airway inflammatory responses to oxidative stress induced by low-dose diesel exhaust particle exposure differ between mouse strains. Exp. Lung Res. 2007; 33: 227 – 44.en_US
dc.identifier.citedreferencePatton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007; 6: 67 – 74.en_US
dc.identifier.citedreferenceMunster AM, Rasmussen L, Sidelmann J, Ingemann Jensen J, Bech B, Gram J. Effects of inhaled plasminogen activator on the balance between coagulation and fibrinolysis in traumatized pigs. Blood Coagul. Fibrinolysis 2002; 13: 591 – 601.en_US
dc.identifier.citedreferenceSu X, Looney M, Robriquet L, Fang X, Matthay MA. Direct visual instillation as a method for efficient delivery of fluid into the distal airspaces of anesthetized mice. Exp. Lung Res. 2004; 30: 479 – 93.en_US
dc.identifier.citedreferenceLynch DW, Placke ME, Persing RL, Ryan MJ. Thirteen-week inhalation toxicity of N, N -dimethylformamide in F344/N rats and B6C3F1 mice. Toxicol. Sci. 2003; 72: 347 – 58.en_US
dc.identifier.citedreferenceIrwin RD. A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen. J. Appl. Toxicol. 2006; 26: 72 – 80.en_US
dc.identifier.citedreferenceDill J, Fuciarelli A, Lee K, Mellinger K, Burka L, Roycroft J. Toxicokinetics of propylene glycol mono-t-butyl ether following intravenous or inhalation exposure in rats and mice. Inhal. Toxicol. 2004; 16: 271 – 90.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1440-1681.2008.05011.x.pdf
Size:
263.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.